Skip to main content

Table 3 Biochemical parameters

From: Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography

  Standard of care
(N = 31)
Alirocumab
(N = 30)
P Value
LDL cholesterol, mmol/L
 Baseline 3.18 ± 0.97 3.04 ± 0.78
 After 36 weeks treatment 2.22 ± 0.69 1.32 ± 0.39 < 0.0001
 Changes from baseline −0.96 ± 0.59 −1.72 ± 0.51 < 0.0001
HDL cholesterol, mmol/L
 Baseline 1.30 ± 0.41 1.41 ± 0.61
 After 36 weeks treatment 1.38 ± 0.43 1.48 ± 0.47 0.35
 Changes from baseline 0.08 ± 0.36 0.07 ± 0.38 0.74
Triglycerides, mmol/L
 Baseline 1.56 (1.19 to 2.38) 1.84 (1.19 to 2.56)
 After 36 weeks treatment 1.53 (1.09 to 2.26) 1.54 (1.00 to 2.09) 0.68
 Changes from baseline −0.05 (0.64 to 1.42) −0.29 (− 0.96 to 0.35) 0.077
CRP, mg/L
 Baseline 1.62 (0.90 to 3.00) 1.69 (0.75 to 3.37)
 After 36 weeks treatment 1.10 (0.89 to 2.50) 1.59 (0.92 to 2.61) 0.64
 Changes from baseline 0.54 (−0.46 to 1.34) 0.12 (−0.74 to 1.08) 0.50
  1. CRP C-reactive protein, LDL low-density lipoprotein, HDL high-density lipoprotein